Olathe, Kan., September 1, 2015 – ELIAS Animal Health, a clinical stage development company advancing novel targeted T cell-based immunotherapy for the treatment of cancer in companion animals, today announced it has filled the remaining appointments to the company’s scientific advisory board with the additions of Ronald Schultz, PhD, and Noe Reyes, DVM. They join board chair Kevin Schultz, DVM, PhD, and Ralph Richardson, DVM, on the advisory board, which is tasked with offering strategic guidance on the advancement of therapies in development and exploring new therapeutic areas in which the company’s technology would be applicable.
Dr. Ron Schultz is a recognized leader on veterinary vaccines, virology and immunology. He currently serves as professor and chair of the Department of Pathobiological Sciences at the School of Veterinary Medicine at the University of Wisconsin-Madison. His primary emphasis of research focuses on the pathogenesis of viral infections in large and companion animals. He earned his doctoral degree from Pennsylvania State University, and is an honorary diplomate from the American College of Veterinary Microbiology.
Dr. Reyes is the medical director for Kindred Biosciences, a development-stage veterinary biopharmaceutical company. His background also includes scientific positions with Achaogen and Theravance Biopharma, as well as the United States Army Veterinary Corps, where he was responsible for the medical care of military working dogs and equine at installations in California and Texas. Dr. Reyes received his doctor of veterinary medicine degree from the University of California, Davis.
“We are delighted to have the additions of Drs. Schultz and Reyes to our scientific advisory board,” said Tammie Wahaus, chief executive officer, ELIAS Animal Health. “Their combined expertise in veterinary immunology enhances our ability to bring our T cell-based immunotherapy technology to market in a segment of veterinary medicine in need of additional treatment outcomes.”
Stephens & Associates Advertising
Veterinarians interested in more information on the clinical program, please visit www.eliasanimalhealth.com or contact ELIAS at email@example.com. Interested investors may contact firstname.lastname@example.org.
About ELIAS Animal Health
Based in Olathe, Kan., ELIAS Animal Health is a medical biotechnology company advancing its novel targeted T cell-based immunotherapies for the treatment of canine cancers. The ELIAS cancer immunotherapy is being distributed to veterinarians under 9 CFR 103.3 as an experimental product. The company’s novel therapeutic approach offers the promise of improved clinical outcomes and the potential for fundamentally changing the way cancer is treated. For more information, please visit www.eliasanimalhealth.com.